AMG 451; a subcutaneous afucosylated IgG1 monoclonal antibody that targets OX40 (CD134), blocking OX40/OX40L costimulatory signaling and depleting OX40-positive activated T cells via ADCC to reduce sustained T-cell activation and type 2 inflammation.
Afucosylated IgG1 monoclonal antibody targeting OX40 (CD134) that blocks OX40/OX40L costimulatory signaling and depletes OX40-positive activated T cells via enhanced ADCC, reducing sustained T-cell activation and type 2 inflammatory responses.
Antibody binds OX40 on activated T cells and, via its afucosylated IgG1 Fc, engages FcγRIIIa on NK cells to drive enhanced ADCC, leading to lysis/apoptosis of OX40+ cells (with possible ADCP by myeloid cells).
Glycoengineered type II humanized anti-CD20 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct cell death, with limited complement activation.
Glycoengineered humanized IgG1 type II anti‑CD20 mAb that binds CD20 on B cells and depletes CD20+ cells via enhanced FcγRIIIa‑mediated ADCC and antibody‑dependent phagocytosis, plus direct caspase‑independent cell death, with minimal complement activation.
Binds CD20 on B cells and depletes them via enhanced Fc-gamma RIIIa–mediated ADCC and antibody-dependent phagocytosis, plus direct caspase-independent cell death (minimal complement).
A bispecific monoclonal antibody T‑cell engager (REGN5458) that binds BCMA on myeloma cells and CD3 on T cells to redirect CD3+ T cells to kill BCMA+ malignant plasma cells.
Linvoseltamab (REGN5458) is a bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, redirecting and activating CD3+ T cells to form cytolytic synapses and kill BCMA-expressing malignant plasma cells.
Bispecific antibody links CD3+ T cells to BCMA+ cells, forming cytolytic synapses and triggering T-cell–mediated killing via perforin/granzyme-induced apoptosis of BCMA-expressing cells.
Ac-225–labeled GPC3-binding radioligand therapy that delivers short-range, high-LET alpha particles to GPC3-positive cells, inducing DNA double-strand breaks and cell death.
RYZ801 is an Ac-225–labeled GPC3-targeted radioligand that binds GPC3 on tumor cells and delivers short-range, high–linear energy transfer alpha particles. The emitted alpha radiation causes clustered DNA double-strand breaks in GPC3-positive cells, leading to irreparable damage and cell death while limiting off-target exposure due to the short path length.
The Ac-225–labeled GPC3-targeted radioligand binds GPC3 and emits short-range alpha particles that induce clustered DNA double-strand breaks in GPC3-positive cells, causing irreversible damage and cell death.
An intravenously administered tetra-specific antibody (biologic immunotherapy) engineered to engage CD3 on T cells and recognize multiple B-cell-associated antigens to redirect and activate T cells against B-cell lymphoma, aiming to enhance cytotoxicity, provide costimulation/checkpoint modulation, and reduce antigen escape.
Tetra-specific T-cell–redirecting antibody that binds CD3 on T cells, CD19 on B-cell lymphomas, PD-L1 to block PD-1–mediated inhibition, and 4-1BB to provide costimulation. By crosslinking T cells to CD19+ tumor cells, it induces CTL-mediated killing while concurrently enhancing activation and persistence and reducing antigen escape.
By binding CD3 on T cells and CD19 on target cells, it crosslinks and activates T cells (augmented by 4-1BB costimulation and PD-L1 blockade) to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity.